January IPO summary: Among the most beautiful IPOs, the highest profit of one signing was over 30,000! Accelerate the pace of issuance of Hong Kong stocks

Market trading of the Beijing Stock Exchange will be launched soon

Gelonghui FinanceJan 31, 2023 16:59

Zero revenue, net loss of 349 million, Jingfeng Medical went public with a valuation of 1.5 billion US dollars

Benchmarking intuitive surgery companies, the valuation skyrocketed from 43 million yuan to 1.5 billion US dollars within four years. What kind of business is Jingfeng Medical in?

36氪May 18, 2022 18:32

What is the underlying logic of medical device investment? Jingfeng Healthcare submitted to the Hong Kong Stock Exchange may be worth paying attention to

Since the second half of last year, the pharmaceutical sector has been in the midst of a pullback, but when the overall shock in the industry was brewing, differentiation also began to occur. A number of high-quality targets began to appear on various segmented tracks, and past accumulation became the driving force for enterprises to stand out during the period of industry evolution. Judging from the experience of the more mature US pharmaceutical sector, in various segments, the medical device sector is the most likely circuit for big bullish stocks to appear. The author is concerned that Jingfeng Medical, a world-leading company in the field of endoscopic surgical robots, recently submitted to the Hong Kong Stock Exchange and is worth studying. Why should we pay more attention to “equipment”? Before analyzing Jingfeng Medical, let's first

Gelonghui FinanceMay 12, 2022 09:53

Jingfeng Medical submits that the Hong Kong Stock Exchange pioneered the field of porous and single-hole endoscopic surgical robots in China

Gelonghui, April 20 丨 Hong Kong Stock Exchange documents show that on the evening of April 19, Shenzhen Jingfeng Medical Technology Co., Ltd. (“Jingfeng Medical”) submitted A1 listing application materials. Morgan Stanley, CICC, and Citi acted as co-sponsors. According to the prospectus, Jingfeng Medical is the world's leading and rapidly growing surgical robotics company committed to designing, developing, manufacturing and commercializing surgical robots. According to Frost & Sullivan's data, the company has now initiated key clinical trials of porous and single-hole endoscopic surgical robots. It is the first in China and one of only two companies in the world. At present, the company has completed

Gelonghui FinanceApr 20, 2022 10:21

New stock news | Shenzhen Jingfeng Medical Technology delivery Table HKEx motherboard is the first clinical trial company in China to launch porous and single-hole endoscopic surgery robots.

Zitong Financial APP learned that Shenzhen Jingfeng Medical Technology Co., Ltd. submitted an application to the HKEx for listing on the main board, with Morgan Stanley, China International Capital Corporation and Citigroup as co-sponsors, according to the Hong Kong Stock Exchange on April 19. Shenzhen Jingfeng Medical Technology Co., Ltd. is a leading and fast-growing surgical robot company in the world, dedicated to the design, development, manufacture and commercialization of surgical robots. According to Frost Sullivan, the company has launched key clinical trials of porous and single-hole endoscopic surgery robots, and is one of the first companies in China and only two companies in the world. The company has completed Jingfeng ®

Zhitong FinanceApr 19, 2022 23:40